Pfizer gains option to buy liver gene therapy company Vivet

Pfizer's latest gene therapy deal gives it a 15% stake in Vivet and comes with an exclusive option to buy the rare liver disease company after the French company advances its Wilson disease candidate through Phase I/II testing that is slated to start next year.

Vivet Therapeutics (Paris, France) received €45 million ($51.1 million) up front from Pfizer Inc. (NYSE:PFE) and could receive up to €560 million ($635.6 million) through exercise of the option and certain clinical, regulatory and commercial milestones related to VTX-801...